{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:43:53Z","timestamp":1787013833241,"version":"build-2736575974"},"reference-count":38,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Abrocitinib efficacy by comorbidity status in patients with moderate\u2010to\u2010severe atopic dermatitis (AD) has not been previously assessed. This post hoc analysis evaluated the efficacy and safety of abrocitinib in patients with AD and allergic comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were pooled from patients who received abrocitinib 200\u2009mg, 100\u2009mg, or placebo in phase 2b (NCT02780167) and phase 3 (NCT03349060, NCT03575871) monotherapy trials. Patients with and without allergic comorbidities (allergic asthma, rhinitis, conjunctivitis, or food allergy) were evaluated for Investigator's Global Assessment (IGA) response (clear [0] or almost clear [1]), \u226575% improvement in the Eczema Area and Severity Index (EASI\u201075), \u22654\u2010point improvement in Peak Pruritus Numerical Rating Scale (PP\u2010NRS4), and Dermatology Life Quality Index (DLQI) response (&lt;2 with baseline score \u22652). Other outcomes were Patient\u2010Oriented Eczema Measure (POEM), SCORing Atopic Dermatitis (SCORAD), Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD), and treatment\u2010emergent adverse events (TEAEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 942 patients, 498 (53%) reported at least one allergic comorbidity (asthma only, 33%; conjunctivitis only or rhinitis only or both, 17%; food allergies only, 15%; &gt;1 allergic comorbidity, 34%). Regardless of comorbidity status, from Week 2 to Week 12, higher percentages of patients treated with either abrocitinib dose achieved IGA 0\/1, EASI\u201075, PP\u2010NRS4, or DLQI 0\/1 versus placebo\u2010treated patients. Changes from baseline in POEM, SCORAD, and PSAAD were greater with abrocitinib than with placebo in patients with and without allergic comorbidities. Most TEAEs were mild or moderate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Efficacy and safety data support abrocitinib use to manage AD in patients with or without allergic comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/all.15952","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T14:46:06Z","timestamp":1700664366000},"page":"174-183","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficacy and safety of abrocitinib in patients with moderate\u2010to\u2010severe atopic dermatitis and comorbid allergies"],"prefix":"10.1111","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3215-3370","authenticated-orcid":false,"given":"Peter","family":"Schmid\u2010Grendelmeier","sequence":"first","affiliation":[{"name":"Allergy Unit, Department of Dermatology University Hospital of Zurich  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0113","authenticated-orcid":false,"given":"Melinda J.","family":"Gooderham","sequence":"additional","affiliation":[{"name":"SKiN Centre for Dermatology Queen's University, and Probity Medical Research  Peterborough Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4595-8226","authenticated-orcid":false,"given":"Karin","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Division of Allergy, Department of Dermatology University Hospital Basel and University of Basel  Basel Switzerland"},{"name":"Department of Biomedicine University Hospital Basel and University of Basel  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1371-6764","authenticated-orcid":false,"given":"George N.","family":"Konstantinou","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology 424 General Military Training Hospital  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-698X","authenticated-orcid":false,"given":"Marc","family":"Fellmann","sequence":"additional","affiliation":[{"name":"Pfizer Switzerland AG  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Koulias","sequence":"additional","affiliation":[{"name":"Pfizer Hellas SA  Athens Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2586-891X","authenticated-orcid":false,"given":"Claire","family":"Clibborn","sequence":"additional","affiliation":[{"name":"Pfizer Ltd.  Surrey United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Biswas","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3488-3345","authenticated-orcid":false,"given":"Patrick M.","family":"Brunner","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,11,21]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.04.020"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.11.006"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1398-9995.2000.00391.x"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.019"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12095"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.01.009"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.042"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14891"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.01.003"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2007.04.007"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.88"},{"issue":"8","key":"e_1_2_12_14_1","first-page":"1079","article-title":"Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications","volume":"137","author":"Elias PM","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011040"},{"key":"e_1_2_12_16_1","volume-title":"Cibinqo 100 mg Film\u2010Coated Tablets (Summary of Product Characteristics)","author":"Pfizer Ltd","year":"2021"},{"key":"e_1_2_12_17_1","volume-title":"Japan'S MHLW Approves PFIZER'S CIBINQO\u00ae (ABROCITINIB) for Adults and Adolescents with Moderate to Severe Atopic Dermatitis [Press Release]","year":"2021"},{"key":"e_1_2_12_18_1","volume-title":"CIBINQO (abrocitinib) tablets, for oral use [prescribing infromation]","author":"Pfizer Inc","year":"2022"},{"key":"e_1_2_12_19_1","volume-title":"CIBINQO\u00ae (Abrocitinib). Summary of Product Characteristics (SmPC)","author":"European Medicines Agency","year":"2021"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.2855"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17744"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.12.059"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.12.151"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.12.523"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19232"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2019.0025"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.09.020"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2017.03.008"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.7.2264"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13954"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.127"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16219"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.053"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00583-3"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2049588"},{"key":"e_1_2_12_39_1","unstructured":"Staumont\u2010Sall\u00e9D BarbarotS BouazizJD et\u00a0al.Effect of abrocitinib and dupilumab on eosinophil levels in the JADE COMPARE Phase 3 clinical trial. 30th EADV Congress; September 29\u2010October 2 2021 2021; Virtual."}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.15952","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T06:52:03Z","timestamp":1708411923000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/all.15952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,21]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/all.15952"],"URL":"https:\/\/doi.org\/10.1111\/all.15952","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,21]]},"assertion":[{"value":"2023-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}